Virpax Pharmaceuticals, Inc.
VRPX Healthcare Biotechnology
In the quarter to December 2024, EPS grew 153.6% and free cash flow grew 4.68%, each against the same quarter a year earlier.
Follow VRPX
Virpax Pharmaceuticals, Inc. (VRPX) Dividend Safety Score
Dividend Safety Score, annual
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | — |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | — |
| VRPX Virpax Pharmaceuticals, Inc. | — |
| CDT CDT Equity Inc. compare | — |
| VINC Vincerx Pharma, Inc. compare | — |
| ATXI Avenue Therapeutics, Inc. compare | — |
| SEELQ Seelos Therapeutics, Inc. compare | — |
| EFTR eFFECTOR Therapeutics, Inc. compare | — |
| CERO CERo Therapeutics Holdings, Inc. compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings